Figure S3.

Figure S3. No improvement of motor function or survival by Sephin1 treatment in SOD1^G93A female mice.

(A) Body weight measurement over the 12 wk of treatment with vehicle, Sephin1 4 mg/kg or Sephin1 8 mg/kg (P = 0.0256 vehicle versus Sephin1 4 mg/kg at 20 wk, mixed effects analysis followed by Tukey’s multiple comparisons test n = 22 mice per condition). (B) Weekly measurement of the latency to fall in rotarod test of SOD1^G93A mice treated with vehicle, Sephin1 4 mg/kg or Sephin1 8 mg/kg n = 22 mice per condition. (C) Weekly measurement of hanging time in the grip test of SOD1^G93A mice treated with vehicle, Sephin1 4 mg/kg or Sephin1 8 mg/kg n = 22 mice per condition. (D) Disease onset of SOD1^G93A mice treated with vehicle, Sephin1 4 mg/kg or Sephin1 8 mg/kg n = 13 mice per condition. (E) Probability of survival from disease onset of SOD1^G93A mice treated with vehicle, Sephin1 4 mg/kg or Sephin1 8 mg/kg n = 13 mice per condition.